Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives

Alicia Padilla Galo1 Unit of Pneumology, Agencia Sanitaria Costa del Sol, Marbella, Málaga, Spain

Marina Labor2 Department of Pulmonology, University Hospital Center Osijek, Osijek, Croatia;3 Faculty of Medicine, J.J. Strossmayer University of Osijek, Osijek, Croatia

Angelica Tiotiu4 Department of Pulmonology, CHRU Nancy, DevAH–Development, Adaptation and Disadvantage, Cardiorespiratory Regulations and Motor Control, University of Lorraine, Nancy, France, [email protected]Correspondence[email protected]

Ilaria Baiardini5 Department of Biomedical Sciences, Humanitas University, Milan, Italy

Nicola Scichilone6 Department of Biomedicine and Internal and Specialistic Medicine (DIBIMIS), University of Palermo, Palermo, Italy

Fulvio Braido7 Department of Internal Medicine, Respiratory Diseases and Allergy Clinic, University of Genova – Azienda Policlinico IRCCs San Martino, Genova, Italy

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives

Articles from other publishers (5)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives

Citations (5)

Articles from other publishers (5)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date